* Amgen Inc., of Thousand Oaks, Calif., said Neupogen (rHuG-CSF)was approved in the U.K. as a supportive therapy to treat neutropeniain people with advanced HIV infection, enabling them to receivemyelosuppressive therapies. Studies in that indication are ongoing inthe U.S.

* Diacrin Inc., of Charlestown, Mass., said the underwriters of itsrecent initial public offering exercised overallotment options on375,000 units, bringing gross proceeds from the offering to $23million.

* NABI, of Boca Raton, Fla., said purchasers of its 6.5 percentconvertible subordinated notes due 2003 exercised theiroverallotment option and purchased an additional $10.5 millionprincipal amount of notes. Total proceeds from the placement of thenotes is $80.5 million.

* Sparta Pharmaceuticals Inc., of Research Triangle Park, N.C.,completed a private placement of $3 million of convertible preferredstock. The stock can be converted at any time at $2.25 per share, andautomatically converts during the next equity offering of at least $2.5million at the lesser of $2.25 or 75 percent of the stock price in thatoffering.

* Viragen Inc., of Hialeah, Fla., will conduct an investigational studyin Florida of its natural interferon product, Alpha Leukoferon, to treatHIV/AIDS in hemophiliacs. The open-label study involving 90patients will be conducted under Florida's Investigational DrugProgram. Sixty patients will receive the product in combination withexisting therapies, while the other 30 will act as the control group.

* Neurobiological Technologies Inc., of Richmond, Calif., sold330,000 shares to underwriters for its February 1996 public offeringboosting proceeds to $7.4 million. Van Kasper & Co., of SanFrancisco, and Gerard Lauer Mattison & Co. LLC., of New York,bought the shares to cover overallotments. Neurobiological sold atotal of 2.5 million shares in the offering at $3.25 per share. Thecompany has 6.5 million shares outstanding.

* SciClone Pharmaceuticals Inc., of San Mateo, Calif., said interimdata from its Phase III Taiwan study of Zadaxin (thymosin alpha I)for hepatitis B showed the drug achieved statistically significantresponse rates. The company said responses were defined asreductions to undetectable levels of hepatitis B virus DNA, anindication of viral load, and hepatitis B e-antigen, a viral replicationprotein.

(c) 1997 American Health Consultants. All rights reserved.